Trisomy 13 (Patau Syndrome): Symptoms, Risks & Treatment
This paper provides a comprehensive overview of Trisomy 13, also known as Patau Syndrome, a rare chromosomal condition in which a person carries three copies of chromosome 13 instead of the normal two. The paper traces the syndrome's history from its first clinical description in 1657 to its genetic characterization in 1960, then examines its symptoms, incidence, and affected populations. Risk factors including maternal age, genetic carriers, and predisposition to meiotic non-disjunction are discussed alongside diagnostic methods, known complications, and management strategies. The paper also addresses long-term prognosis and current research efforts by institutions such as NICHD.
- Introduction to Trisomy 13: History, genetics, and core symptoms of Patau Syndrome
- Incidence of Disease: How frequently Trisomy 13 occurs in newborns
- Risk Factors: Maternal age, genetics, and other contributing risk factors
- Treatments and Management: Diagnostic procedures and clinical management strategies
- Known Complications with Diagnosis: Survival rates and major complications of Trisomy 13
- Prehospital and Prenatal Screening Considerations: Ultrasound and marker screening for prenatal detection
- Long-Term Prognosis and Ongoing Research: Survival outlook and institutional research programs
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Covers the topic systematically, moving from historical background and genetics through incidence, risk factors, diagnosis, complications, prognosis, and research — giving the reader a complete clinical picture.
- Integrates specific clinical terminology (microphthalmia, holoprosencephaly, meiotic non-disjunction) appropriately, demonstrating engagement with primary and secondary medical sources.
- Uses quantitative data effectively — survival rates, incidence figures, and median survival times — to ground clinical claims in evidence.
Key academic technique demonstrated
The paper demonstrates effective synthesis of multiple source types — peer-reviewed studies, government health databases, and clinical references — to build a unified, evidence-based description of a rare genetic disorder. Each section draws on distinct sources while maintaining a coherent argument about the severity and complexity of Trisomy 13.
Structure breakdown
The paper is organized into seven thematic sections. It opens with a historical and genetic introduction, then addresses incidence and epidemiology before moving into risk stratification. Diagnostic methods and management strategies are discussed in a dedicated section, followed by known complications and survival data. Prenatal screening considerations are treated separately before the paper closes with long-term prognosis and a summary of active institutional research efforts.
Introduction to Trisomy 13
Trisomy 13, also known as Patau Syndrome, is a genetic disease in which a person carries three copies of the genetic material from chromosome 13 instead of the normal two copies. It occurs when extra DNA from chromosome 13 appears in some or all of the body's cells. The treatment of this disorder differs from child to child and depends on the individual's symptoms.
Patau Syndrome was characterized in 1960 by Klaus Patau, a German-American geneticist, working alongside his research colleagues. However, the syndrome's clinical appearances were first described as early as 1657 by Erasmus Bartholin, who did not know its aetiology (Patient Information, n.d.). Trisomy 13 is a chromosomal condition linked with severe physical and intellectual disability. Those affected typically present with spinal or brain abnormalities, heart defects, and smaller, underdeveloped eyes — a condition referred to as microphthalmia — as well as cleft lip, extra toes or fingers, and hypotonia. Because of the life-threatening problems that accompany the condition, most children with Trisomy 13 succumb to it within the first few weeks of life. Only 5% to 10% of children with the condition survive to see their first birthday (Genetics Home Reference, 2017).
Most cases of Trisomy 13 result from having three copies of chromosome 13 in the body's cells rather than the normal two. This disrupts the body's development and produces the symptoms that characterize the condition. Trisomy 13 can also develop when a portion of chromosome 13 attaches to another chromosome as reproductive cells form during early fetal development. Those affected in this way carry the usual two copies of chromosome 13 but also have an extra segment of chromosome 13 attached to one of the other chromosomes. In some instances, only a portion of chromosome 13 appears in three copies. The signs and symptoms in these partial cases often differ from those observed when full Trisomy 13 is present (Genetics Home Reference, 2017).
The occurrence of Trisomy 13 is approximately one in every 16,000 newborns. Although Trisomy 13 can occur in a child conceived by a woman of any age, the risk increases with the mother's age (Genetics Home Reference, 2017).
Incidence of Disease
Patau Syndrome is the third most frequently occurring chromosomopathy. One in every 16,000 newborns carries Trisomy 13, and 80% of cases involve a fresh mutation with meiotic non-disjunction originating from the mother. Translocation forms are not uncommon. An affected newborn is likely to present with polydactyly, cheilognathopalatoshisis, microphthalmia, dolichocephaly, and microcephaly. The brain is also likely to show changes detectable by ultrasound (Misanovic, Jonuzi, Bisacevic, & Vegar, 2002).
A large proportion of fetuses with the condition die in utero or are stillborn. Of those born alive, only 20% survive past the first month, and just 5% live past six months (Fleischer et al., 2011).
Risk Factors
A personal or family history of bearing children with the condition constitutes a risk factor. Risk also increases with maternal age, though not to the same degree as with Down Syndrome or Edwards' Syndrome (Patient Information, n.d.).
Maternal Age: The occurrence of meiotic non-disjunction — the failure of chromosomes to separate properly during meiosis — increases with maternal age. Older women therefore face a higher risk of giving birth to children with the condition. The average age of mothers who bear children with Trisomy 13 is 31 (Natural Standard, 2011).
Genetic Carriers: People with translocations involving chromosome 13 may bear children with Trisomy 13. Studies have indicated that parental origin may be a factor in determining the risk of inheriting the responsible translocation trisomies. Paternal translocations are less likely to be inherited than maternal translocations.
Predisposition to Meiotic Non-Disjunction: Some mothers have been reported to have a higher predisposition to meiotic non-disjunction, and therefore face a greater risk of bearing a child with trisomies. While the additional risk for mothers who previously bore a child with Trisomy 21 is low, it is statistically significant. Cases of both Trisomy 13 and Trisomy 21 occurring within the same family have been reported (Natural Standard, 2011).
Other Factors: Gender and race have been reported to influence the longevity of Trisomy 13 patients. Non-white females tend to have longer than median survival times. It has also been reported that gestational obesity and maternal obesity may increase the risk of Trisomy 13, though these claims are not conclusively supported by evidence (Natural Standard, 2011).
Create your account
Always verify citation format against your institution’s current style guide requirements.